

# Influence of natalizumab on resting-state connectivity in patients with multiple sclerosis

Diogo G. Corrêa<sup>1,2</sup> , Eelco van Duinkerken<sup>3,4</sup>,  
João Gabriel D. Farinhias<sup>4,5</sup> , Valéria C. Pereira<sup>5</sup>,  
Emerson L. Gasparetto<sup>1</sup>, Soniza V. Alves-Leon<sup>4,5</sup> and  
Fernanda Cristina R. Lopes<sup>1,2</sup>

<sup>1</sup>Department of Radiology, Clínica de Diagnóstico por Imagem (CDPI)/DASA, Barra da Tijuca, Brazil.

<sup>2</sup>Department of Radiology, Federal Fluminense University, Niterói, Brazil. <sup>3</sup>Department of Medical Psychology, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands.

<sup>4</sup>Post-Graduate Program in Neurology, Hospital Universitário Gaffrée e Guinle, Universidade Federal do Estado do Rio de Janeiro, Rio de Janeiro, Brazil. <sup>5</sup>Department of Neurology, Hospital Universitário Clementino Fraga Filho, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.

Journal of Central Nervous System Disease

Volume 15: 1–10

© The Author(s) 2023

Article reuse guidelines:

[sagepub.com/journals-permissions](https://sagepub.com/journals-permissions)

DOI: 10.1177/11795735231195775



## ABSTRACT

**BACKGROUND:** Changes in brain connectivity occur in patients with multiple sclerosis (MS), even in patients under disease-modifying therapies. Using magnetic resonance imaging (MRI) to assess patients treated with disease-modifying therapies, such as natalizumab, can elucidate the mechanisms involved in clinical deterioration in MS.

**OBJECTIVES:** To evaluate differences in resting-state functional connectivity among MS patients treated with natalizumab, MS patients not treated with natalizumab, and controls.

**DESIGN:** Single-center retrospective cross-sectional study.

**METHODS:** Twenty-three MS patients being treated with natalizumab were retrospectively compared with 23 MS patients who were naïve for natalizumab, and were using first-line medications (interferon-β and/or glatiramer acetate), and 17 gender- and age-matched control subjects. The MS patient groups were also matched for time since diagnosis and hyperintense lesion volume on FLAIR. All participants underwent brain MRI using a 3 Tesla scanner. Independent component analysis and dual regression were used to identify resting-state functional connectivity using the FMRIB Software Library.

**RESULTS:** In comparison to controls, the MS patients treated with natalizumab presented decreased connectivity in the left orbitofrontal cortex, in the anterior cingulate and orbitofrontal cortex network. The patients not treated with natalizumab presented increased connectivity in the secondary visual, sensorimotor, and ventral attention networks in comparison to controls.

Compared to patients treated with natalizumab, the patients not using natalizumab presented increased connectivity in the left Heschl's gyrus and in the right superior frontal gyrus in the ventral attention network.

**CONCLUSION:** Differences in brain connectivity between MS patients not treated with natalizumab, healthy controls, and patients treated with natalizumab may be secondary to suboptimal neuronal compensation due to prior less efficient treatments, or due to a compensation in response to maladaptive plasticity.

**KEYWORDS:** Multiple sclerosis, natalizumab, resting-state functional imaging

**TYPE:** Original Research Article

**DECLARATION OF CONFLICTING INTERESTS:** The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**FUNDING:** The author(s) received no financial support for the research, authorship, and/or publication of this article.

**AUTHOR'S NOTE:** Diogo Goulart Corrêa: Conceptualization, Methodology, Writing – original draft, Eelco van Duinkerken: Data curation, Formal analysis, Methodology, Software, Writing – original draft, João Gabriel Dib Farinhias: Formal analysis, Investigation, Methodology, Writing – original draft, Valéria Coelho Pereira: Data curation, Formal analysis, Methodology, Project administration, Writing – original draft, Emerson Leandro Gasparetto: Conceptualization, Formal analysis, Investigation, Project administration, Supervision, Writing – review & editing, Soniza Vieira Alves-Leon: Formal analysis, Methodology, Project administration, Supervision, Validation, Writing – review & editing, Fernanda

Cristina Rueda Lopes: Formal analysis, Methodology, Project administration, Supervision, Visualization, Writing – review & editing.

**ETHICS APPROVAL AND CONSENT TO PARTICIPATE:** All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional review board of the Clementino Fraga Filho University Hospital (research protocol: 169/08) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Written informed consent was obtained from all the participants included in the study.

**CONSENT FOR PUBLICATION:** Not applicable.

**AVAILABILITY OF DATA AND MATERIAL:** Available upon relevant requests.

**CORRESPONDING AUTHOR:** Diogo G. Corrêa, Department of Radiology, Universidade Federal Fluminense, Rua Marquês de Paraná, 303, Niterói, Rio de Janeiro 2033-900, Brazil. Email: [diogogoulartcorrea@yahoo.com.br](mailto:diogogoulartcorrea@yahoo.com.br)



Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (<https://creativecommons.org/licenses/by-nc/4.0/>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<https://us.sagepub.com/en-us/nam/open-access-at-sage>).

## Introduction

Multiple sclerosis (MS) is an immune-mediated demyelinating disease of the central nervous system (CNS), which leads to widespread brain and spinal cord lesions,<sup>1,2</sup> with early inflammation, causing relapsing-remitting disease and delayed neurodegeneration causing nonrelapsing progression.<sup>3</sup> The current therapeutic strategies for MS aims to reduce the risk of relapse and disability progression.<sup>4</sup> In recent years, the number of therapeutic options for MS expanded widely. Several disease-modifying therapies (DMTs) for MS were approved by the European Medicines Agency and U.S. Food and Drug Administration in both injectable and oral formulations. However, the growth in the number of therapies brings new challenges for individualized treatment in terms of the relative efficacy of the drugs available, identifying which patients should receive therapy, and recognizing the optimum time to start treatment. There is currently no consensus among physicians to classify patients into high-risk and low-risk groups to prioritize treatment strategies<sup>5</sup>; however, early treatment with highly effective DMTs is increasingly recommended.<sup>6</sup>

Natalizumab is a humanized monoclonal antibody. It targets the α4-integrin, which is present on white blood cells involved in inflammation, and it prevents the movement of mononuclear leukocytes to inflamed tissues, including those in the CNS.<sup>7</sup> High efficacy DMTs like natalizumab have a higher risk of serious adverse events than lower efficacy medications, such as interferon, such as progressive multifocal leukoencephalopathy, a disease caused by reactivation of the John Cunningham virus (JCV) or *de novo* infection.<sup>1</sup>

Brain MRI is fundamental for MS diagnosis. MRI is used to visualize the distribution of the disease in the CNS over time, to exclude other conditions,<sup>2,8</sup> and to monitor disease evolution, and treatment effects.<sup>9</sup> However, the association between conventional neuroradiological markers of MS and clinical disability has been weak due to several factors.<sup>10</sup> These factors include the limited sensitivity of clinical outcome measures, such as the Expanded Disability Status Scale (EDSS), the inability of conventional MRI to measure remyelination, and the emphasis of MRI on detection of focal white matter pathology.<sup>9</sup>

The use of functional MRI can provide novel biomarkers to gather important *in vivo* information on brain activity following tissue injury.<sup>11</sup> In contrast with structural magnetic resonance techniques, which have allowed the extent and severity of MS brain damage to be qualified, functional MRI has demonstrated that cortical reorganization might play a role in the clinical consequences of tissue damage.<sup>12</sup> The scattered nature of MS lesions may be effectively studied using network analyses. Analysis of brain functional networks in MS has led to several observations. For instance, this type of analysis has shown that there is a high likelihood of altered connectivity in basal ganglia, a decrease

in brain modularity, hemispheric asymmetries in connectivity alterations, and a correspondence of behavioral symptoms with task-related and task-unrelated networks.<sup>13</sup> Previous studies showed contrasting results in the alterations of resting state networks in MS, related to clinical disability, with both increased and decreased connectivity in the motor areas, cerebellum and other networks, including the default mode and fronto-parietal. This suggests the co-occurrence of adaptive and maladaptive responses within networks, which vary according to patients' clinical characteristics. Also, both increased and decreased connectivity in the default mode network has been related to cognitive impairment, indicating that hyper- and hypo-connected networks lead to an inefficient cognition.<sup>14</sup>

To date, however, no studies have evaluated the effects of natalizumab on brain connectivity of patients with MS, without progressive multifocal leukoencephalopathy. Therefore, the aim of this study is to analyze resting-state functional connectivity in MS patients treated with natalizumab in comparison to patients not treated with natalizumab and control subjects.

## Material and Methods

### Subjects

This study was approved by the Institutional Review Board of the Clementino Fraga Filho University Hospital (research protocol: 169/08), and all participants signed informed consent. Between September 2012 and September 2018, 46 right-handed patients with a diagnosis of relapsing-remitting MS according to the 2017 revision of the McDonald criteria<sup>8</sup> were selected from the Demyelinating Disease Outpatient Clinic of the Clementino Fraga Filho University Hospital. Even patients who were diagnosed before 2017, fulfilled the diagnostic criteria for multiple sclerosis according to the 2017 revision of the McDonald criteria, retrospectively. The patients were all in the clinical remission phase of the disease. The exclusion criteria were the presence of other autoimmune diseases diagnosed by clinical and serological tests, reported use of illicit drugs in the previous year, lesions with contrast enhancement observed in the brain MRI (active lesions), and MRI contraindications.

The MS patients were divided into two groups according to their treatment: MS patients treated with natalizumab and MS patients not treated with natalizumab. Twenty-three MS patients were treated with natalizumab for at least 6 months prior to the date of MRI and were never treated with other DMTs. Patients in this group were administered 300 mg natalizumab intravenously as monotherapy once per month for at least 6 months, and none were positive for JCV antibodies. Twenty-three MS patients were receiving medications other than natalizumab, such as interferon-β and/or glatiramer acetate, when the MRI data were acquired, and they were naïve for other DMTs. In some patients who had been previously treated with corticosteroids to control acute relapse, the MRI scans were

performed at least 30 days after the end of this treatment. No participant had active lesions in the MRI. The database also included 17 right-handed healthy controls (11 women and 6 men), who had no clinical or imaging evidence of neurological disease.

### *Magnetic Resonance Imaging Acquisition*

Magnetic resonance imaging was performed with a 3 Tesla scanner (Magnetom Trio, Siemens, Erlangen, Germany) using a standard 8-channel phased-array head coil. The conventional MRI protocol included axial FLAIR with the following conditions: repetition time (TR) = 9000 ms, echo time (TE) = 80 ms, inversion time (TI) = 2500 ms, matrix = 208 × 256, and flip angle = 150°. The protocol also included a high-resolution, sagittal, 3D T1 MPRAGE with the following conditions: TR = 2530 ms, TE = 3.45 ms, TI = 1100 ms, matrix = 256 × 256, flip angle = 7°, and voxel size 1.3 mm × 1.0 mm × 1.3 mm. Resting-state functional MRI (RS-fMRI) was acquired using a T2\*-weighted gradient spin-echo sequence (TE = 30 ms, TR = 3000 ms, 72 × 72 acquisition matrix, flip angle = 85°) that was sensitive to the blood oxygen level-dependent (BOLD) contrast. In total, 36 interleaved, 124 images, with 3 mm thickness and 30% gap were acquired parallel to the anterior commissure plane, totaling 6 minutes and 18 seconds of scanning. Each subject's head was stabilized with tape across the forehead and padding around the sides. Earplugs were used to minimize MRI noise interference. All MRI scans were reviewed by an experienced neuroradiologist (10 years of experience) and were considered of good quality for post-processing.

### *Structural Magnetic Resonance Imaging Analysis*

White matter, gray matter and whole brain volumes (white matter + grey matter), as well as thalami volumes were assessed on 3-dimensional (3D) T1 magnetization-prepared rapid gradient echo (MPRAGE), using an automated online MRI brain volumetry system (volBrain - <https://www.volbrain.upv.es/>). T2-hyperintense lesions volume measurements were performed on fluid-attenuated inversion recovery (FLAIR) images, also in volBrain. This system is primarily based on a multiatlas, patch-based segmentation method and utilizes training libraries implemented in the online platform.<sup>15,16</sup> VolBrain has been previously validated, compared with state-of-the-art methods showing very similar results for brain volumetric measures.<sup>16</sup>

### *Processing of RS-fMRI Data*

RS-fMRI data were preprocessed with FMRIB Software Library (FSL) version 5.0.9 tools (<http://www.fmrib.ox.ac.uk/fsl>). To begin, the first 10 volumes were removed to include only steady-state BOLD volumes. Then, before preprocessing, the necessary matrices and warp volumes to

register the individual RS-fMRI scan to Montreal Neurological Institute (MNI)-152 standard space were calculated. Next, the remaining 114 images were motion-corrected, and non-brain tissue was removed. In addition, the images were spatially smoothed with a 6-mm full width at half maximum (FWHM) Gaussian kernel and temporally filtered using a high-pass filter of 150 s. After this pre-processing, individual functional scans were non-linearly warped to 4-mm MNI-152 standard space using a 10-mm warp resolution.

To correct for motion, scrubbing was applied. First, based on the raw fMRI scans, the FSL's Motion Outliers script was used to calculate the volumes to be scrubbed based on the Frame-wise Displacement (FD) and DVARS (D referring to temporal derivative of time-course and VARS to the root mean squared variance over voxels) combined.<sup>17</sup> Next, the 3dTproject script of AFNI (<https://afni.nimh.nih.gov/>) was used to scrub the pre-processed fMRI scans in 4-mm standard space. Removing volumes leads to fMRI scans of different lengths, which can potentially confound between-group analyses,<sup>18</sup> so we interpolated the values of the to-be scrubbed volumes from the neighboring volumes in time. Therefore, volumes with high motion were censored but not removed. There were no significant differences in motion between the groups ( $P = .457$ , and .383, before and after scrubbing respectively; **Table 1**).

Independent component analysis was used to identify large-scale functional connectivity patterns.<sup>19</sup> The spatial and temporal information was then back-regressed onto the individual fMRI scans in common space using FSL's "dual-regression" approach<sup>20</sup> to allow for voxel-wise between-group comparisons. The functional networks were selected by visual inspection and comparison with earlier studies.<sup>21</sup>

### *Statistical Analysis*

Demographic information was analyzed using IBM SPSS Statistics version 20 (Chicago, IL, USA) using analysis of variance (ANOVA) with post-hoc Bonferroni or the two-sample *t*-test for normally distributed variables, the Kruskal-Wallis test for non-normally distributed variables, and Fisher's exact test for categorical variables. For RS-fMRI, FSL permutation analysis of linear models was used to perform two-sided voxel-wise between-group analyses using a non-parametric general linear model with 10 000 permutations.<sup>22</sup> Multiple comparisons were controlled for by applying threshold-free cluster enhancement and family-wise error correction using age and sex as confounding factors. The following comparisons were made: (1) All MS patients (treated and not treated with natalizumab) vs controls, (2) MS patients treated with natalizumab vs controls, (3) MS patients not treated with natalizumab vs controls, and (4) MS patients treated with natalizumab vs MS patients not treated with natalizumab.  $P < .05$  was considered statistically significant.

**Table 1.** Sociodemographic and Clinical Data of MS Patient Groups and Controls Participants.

	GROUPS	MEAN	STANDARD DEVIATION	F	P
Age in years*	Controls	44.24 (range 21-52)	9.54	1.71	.189
	MSuNat	41.13 (range 29-61)	9.01		
	MSnNat	38.73 (range 28-59)	9.35		
Sex* <sup>1</sup>	Controls	6 M/11 W	—	—	.447
	MSuNat	4 M/19 W	—		
	MSnNat	6 M/17 W	—		
Time since diagnosis (months)* <sup>2</sup>	Controls	—	—	—	.741
	MSuNat	78.91 (range 12-180)	50.87		
	MSnNat	77.00 (range 7-228)	58.24		
RS-fMRI relative displacement ratio before scrubbing*	Controls	.06 (range .02-.17)	.04	.794	.457
	MSuNat	.05 (range .02-.11)	.02		
	MSnNat	.05 (range .01-.21)	.04		
RS-fMRI relative displacement ratio after scrubbing*	Controls	.05 (range .02-.14)	.03	.976	.383
	MSuNat	.04 (range .01-.17)	.02		
	MSnNat	.04 (range .01-.17)	.03		
T2-hyperintense lesion volume seen on FLAIR (absolute volume – cm <sup>3</sup> )* <sup>2</sup>	Controls	— <sup>a</sup>	—	—	.248
	MSuNat	20.67 (range 1.52-80.01)	20.84		
	MSnNat	19.37 (range .32-85.05)	24.57		
T2-hyperintense lesions volume seen on FLAIR (relative volume – normalized by the total intracranial volume - %)* <sup>2</sup>	Controls	— <sup>a</sup>	—	—	.218
	MSuNat	1.50 (range .11-4.92)	1.40		
	MSnNat	1.40 (range .02-5.73)	1.74		
Time using natalizumab (months)	Controls	—	—	—	—
	MSuNat	16.52 (range 6-48)	9.91		
	MSnNat	—	—		
Time elapsed from diagnosis until the start of natalizumab (months)	Controls	—	—	—	—
	MSuNat	62.39 (range 0-152)	45.79		
	MSnNat	—	—		

M = men; W = women; MSuNat = multiple sclerosis patients using natalizumab; MSnNat = multiple sclerosis patients not using natalizumab; RS-fMRI = resting state functional magnetic resonance imaging. Statistical analysis used: \*: ANOVA with post hoc Bonferroni; <sup>1</sup>: Fisher's exact test; <sup>2</sup>: Kruskal-Wallis test.

<sup>a</sup>Control participants had a normal T2-FLAIR or only mild unspecific hyperintensities foci in frontal and parietal white matter. The average absolute volume of these hyperintensities was .21 cm<sup>3</sup> (range 0-1.75 cm<sup>3</sup>), relative volume was .01% (range 0%-14%).

**Table 2.** Mean Absolute and Normalized Brain Volume of the Participants. Note that Although there was Brain Atrophy in MS Patients, Compared to Controls, Because of a Reduction in White Matter and Thalami Volumes, there was No Significant Difference in White Matter, Gray Matter, Thalami and Whole-Brain Volumes Between the Two MS Groups.

VOLUME	GROUPS	MEAN (STANDARD DEVIATION)	P	PAIRWISE COMPARISONS (P)
White matter (absolute volume – cm <sup>3</sup> )*	Controls	487.10 (72.55)	.025	Controls vs MSuNat – .022
	MSuNat	425.75 (69.76)		Controls vs MSnNat – .672
	MSnNat	467.97 (73.78)		MSuNat vs MSnNat – .152
White matter (normalized by the total cranial volume - %)*	Controls	37.20 (2.47)	<.001	Controls vs MSuNat - <.001
	MSuNat	31.70 (3.90)		Controls vs MSnNat – .003
	MSnNat	33.47 (3.84)		MSuNat vs MSnNat – .256
Gray matter (absolute volume – cm <sup>3</sup> )*	Controls	626.02 (75.30)	.299	Controls vs MSuNat – .993
	MSuNat	627.34 (59.75)		Controls vs MSnNat – .372
	MSnNat	653.82 (64.49)		MSuNat vs MSnNat – .407
Gray matter (normalized by the total cranial volume - %)*	Controls	48.05 (3.96)	.388	Controls vs MSuNat – .415
	MSuNat	46.85 (2.67)		Controls vs MSnNat – .429
	MSnNat	46.87 (2.56)		MSuNat vs MSnNat – .999
White matter + gray matter (absolute volume – cm <sup>3</sup> )*	Controls	1113.13 (132.36)	.159	Controls vs MSuNat – .491
	MSuNat	1054.65 (119.86)		Controls vs MSnNat – .776
	MSnNat	1147.88 (214.96)		MSuNat vs MSnNat – .170
White matter + gray matter (normalized by the total cranial volume - %)*	Controls	85.26 (3.79)	<.001	Controls vs MSuNat – <.001
	MSuNat	78.56 (5.10)		Controls vs MSnNat – .004
	MSnNat	80.35 (5.05)		MSuNat vs MSnNat – .452
Right thalamus volume (absolute volume – cm <sup>3</sup> )*	Controls	5.15 (.50)	<.001	Controls vs MSuNat – <.001
	MSuNat	4.06 (.99)		Controls vs MSnNat – .02
	MSnNat	4.42 (.87)		MSuNat vs MSnNat – .36
Right thalamus volume (normalized by the total cranial volume - %)*	Controls	.39 (.03)	<.001	Controls vs MSuNat – <.001
	MSuNat	.30 (.06)		Controls vs MSnNat – <.001
	MSnNat	.31 (.06)		MSuNat vs MSnNat – .63
Left thalamus volume (absolute volume – cm <sup>3</sup> )*	Controls	5.15 (.49)	.004	Controls vs MSuNat – .02
	MSuNat	4.15 (1.08)		Controls vs MSnNat – .025
	MSnNat	4.38 (.97)		MSuNat vs MSnNat – .70
Left thalamus volume (normalized by the total cranial volume - %)*	Controls	.39 (.03)	<.001	Controls vs MSuNat – <.001
	MSuNat	.30 (.06)		Controls vs MSnNat – <.001
	MSnNat	.31 (.06)		MSuNat vs MSnNat – .93


MSuNat = multiple sclerosis patients using natalizumab; MSnNat = multiple sclerosis patients not using natalizumab. Statistical analysis used: \*: ANOVA with post hoc Bonferroni.

## Results

### Participants

The entire MS group included 46 participants (36 women and 10 men). Of the MS patients, 23 were treated with natalizumab (50%), and 23 were not treated with natalizumab (50%). In the MS group not using natalizumab, 10 were using interferon, and

13 were using glatiramer acetate. No participant had a history of using fingolimod or another disease-modifying treatment. The control group included 17 participants (11 women and 6 men). As shown in Table 1, all groups were matched for age and sex. The MS groups were also comparable in terms of disease duration. The MS patients treated with natalizumab had a disease duration of  $78.91 \pm 50.87$  months, and the MS patients



**Figure 1.** Independent component analysis map of the anterior cingulate and orbitofrontal cortex network in green on a 1-mm MNI152 standard brain, for visual purpose. Corrected RS-fMRI maps in the sagittal, coronal, and axial planes that compare all the MS patients (treated and not treated with natalizumab) vs the control group. Blue voxels represent areas with decreased connectivity in the MS group compared to controls present in the left orbitofrontal cortex.

not treated with natalizumab had a disease duration of  $77.00 \pm 58.24$  months ( $P = .741$ ). There was no significant difference in T2-hyperintense lesions volume between the MS patients treated with natalizumab and those not treated with natalizumab (Table 1). Although there was brain atrophy in both MS groups, because of a reduction in white matter and thalami volumes, there was no significant difference in white matter, gray matter, thalami and whole-brain volumes between the two MS groups (Table 2).

#### *Functional Connectivity at Rest*

Independent component analysis identified 37 components of which 15 coincided with resting-state networks described in previous studies. These 15 resting-state networks were the following: primary visual, secondary visual, anterior default mode (with hippocampus), posterior default mode (without hippocampus), dorsal attention, frontal, left frontoparietal, right frontoparietal, cerebellar, auditory, primary sensorimotor, anterior cingulate and orbitofrontal cortex, limbic, basal ganglia, and ventral attention networks.

#### *All Multiple Sclerosis Patients vs Controls*

Compared to controls, the MS patients (those treated and not treated with natalizumab) presented decreased connectivity in voxels in the left orbitofrontal cortex in the anterior cingulate and orbitofrontal cortex network (Figure 1). The other resting-state networks did not show significant differences in connectivity in this comparison.

#### *Multiple Sclerosis Patients Treated With Natalizumab vs Controls*

Compared to controls, MS patients treated with natalizumab presented decreased connectivity in voxels in the left orbitofrontal cortex in the anterior cingulate and orbitofrontal cortex network (Figure 2). The other resting-state networks did not show significant differences in connectivity in this comparison.

#### *Multiple Sclerosis Patients Not Treated With Natalizumab vs Controls*


Compared to controls, MS patients not treated with natalizumab presented increased connectivity in voxels in the left fusiform gyrus in the secondary visual network, in the right precentral gyrus in the sensorimotor network, and in the left supramarginal and right frontal superior gyri in the ventral attention network (Figure 3). The other resting-state networks did not show significant differences in connectivity in this comparison.

#### *Multiple Sclerosis Patients Not Treated With Natalizumab vs Multiple Sclerosis Patients Treated With Natalizumab*


In comparison to MS patients using natalizumab, MS patients not treated with natalizumab presented increased connectivity in voxels in the left Heschl's gyrus and in the right superior frontal gyrus in the ventral attention network (Figure 4). The other resting-state networks did not show significant differences in connectivity in this comparison.

#### **Discussion**

In this study, we used a voxel-wise method to assess RS-fMRI networks through independent component analysis in 23 MS patients treated with natalizumab, 23 MS patients not treated with natalizumab, and 17 control subjects. Our results showed that compared to controls, the group formed by all the MS patients presented decreased connectivity in the anterior cingulate and orbitofrontal cortex network. Furthermore, the MS patients using natalizumab also presented decreased connectivity in the anterior cingulate and orbitofrontal cortex network compared to controls. In contrast, MS patients not using natalizumab presented increased connectivity in the secondary visual, sensorimotor, and ventral attention networks compared to controls, but no differences in the orbitofrontal cortex network. Therefore, at a group level, the decreased anterior cingulate and orbitofrontal cortex network connectivity was entirely




**Figure 2.** Independent component analysis map of the anterior cingulate and orbitofrontal cortex network in green on a 1-mm MNI152 standard brain, for visual purpose. Corrected RS-fMRI maps in the sagittal, coronal, and axial planes that compare MS patients treated with natalizumab vs the control group. Blue voxels represent areas with decreased connectivity in the MS group compared to controls present in the left orbitofrontal cortex. Note the similarity of the altered voxels of MS patients using natalizumab vs controls in relation with the altered voxels in the comparison of all MS patients vs controls.



**Figure 3.** Independent component analysis maps of the secondary visual network (A), sensorimotor network (B), and ventral attention network (C) in green on a 1-mm MNI152 standard brain, for visual purpose. Corrected RS-fMRI maps in the sagittal, coronal, and axial planes that compare MS patients not using natalizumab vs the control group. Red voxels represent areas with increased connectivity in the MS group not using natalizumab compared to the controls. These areas include the left fusiform gyrus in panel A (secondary visual network), right precentral gyrus in panel B (sensorimotor network), and left supramarginal and right frontal superior gyri in panel C (ventral attention network).

driven by those patients using natalizumab. In addition, MS patients not treated with natalizumab presented increased connectivity in the ventral attention network compared to the patients using natalizumab.

The inflammatory process of MS leads to tissue damage within the lesions. In parallel to the disease process, remyelination is possible and can repair damaged tissue to some extent and is observable in all disease stages.<sup>3</sup> In addition to



**Figure 4.** Independent component analysis map of the ventral attention network in green on a 1-mm MNI152 standard brain, for visual purpose. Corrected RS-fMRI maps in the sagittal, coronal, and axial planes that compare MS patients not using natalizumab vs MS patients using natalizumab. Red voxels represent areas with increased connectivity in the MS group not using natalizumab compared to the MS group using natalizumab. These areas are present in the left Heschl's gyrus and the right superior frontal gyrus.

remyelination, there is evidence of reorganization of brain function, secondary to cortical plasticity, which consists of a reorganization of the functional activation of cortical regions to maintain clinical function.<sup>1,23</sup> However, this functional reorganization can be maladaptive and contribute to disability. To date, the effects of DMTs on the mechanisms of brain plasticity are not fully understood.<sup>23</sup> Switching from MS treatment with interferon or glatiramer acetate to natalizumab results in superior outcomes, including a reduced risk of relapse, longer time to relapse, reduced treatment discontinuation events, and reduced disability worsening.<sup>24-26</sup> The escalation treatment approach is presumed to be safer, but carries a risk of suboptimal control of neuroinflammation and subsequent irreversible long-term neurodegeneration. In contrast, early use of DMT might generate better long-term outcomes.<sup>27,28</sup> Guidelines from the American Academy of Neurology, European Committee of Treatment and Research in Multiple Sclerosis, and European Academy of Neurology encourage early initiation of DMT in patients with active relapsing-remitting MS.<sup>27</sup>

The MS patients in the current study had been diagnosed with MS for an average of 78.91 months for those treated with natalizumab and 77 months for those not treated with natalizumab. Some of the patients had been diagnosed with MS for more than 20 years, and were diagnosed prior to the approval of natalizumab for clinical use in 2006. Thus, the MS patients using natalizumab had a history of receiving medications that were less effective, such as interferon, prior to their treatment with natalizumab. One hypothesis for our results is that some participants in the group using natalizumab had their treatments switched to more effective drugs because they initially had poor clinical outcomes with less effective drugs. Meanwhile, participants in the group not treated with natalizumab were not switched to a more effective treatment because they had good responses to interferon or glatiramer. This heterogeneous response to treatment with less effective drugs can occur due to genetic and environmental factors, which are not yet fully known.

The group treated with natalizumab may have lower connectivity in some brain networks compared to the group not

using natalizumab and the controls because they had worse clinical conditions prior to the use of natalizumab. The clinical condition of these patients may be secondary to poor responses to less effective treatments prior to their treatment with natalizumab. This reduction in functional connectivity in the group treated with natalizumab may have occurred due to previous progressive accumulation of structural damage. The patients using natalizumab had been diagnosed with MS for an average of 78.91 months, but were only using natalizumab for 16.52 months. Therefore, these patients may have started an optimal treatment with natalizumab too late to adequately compensate for neuronal damage.

There is an alternative hypothesis to explain our results. Although increased functional connectivity is generally considered an adaptation to compensate for tissue damage, it can also represent maladaptive plasticity secondary to disease activity.<sup>29</sup> Therefore, the increased connectivity seen in patients not using natalizumab may represent a failed attempt to compensate for brain lesions due to neuroinflammation and be the result of suboptimal treatment. However, on the other hand, it should also be considered that recent reviews described that several studies have found increased connectivity to be related with cognitive impairment, whereas other studies have found decreased connectivity to be related with cognitive impairment in MS.<sup>14,30</sup> Additionally, other studies found both increased and decreased connectivity in different brain regions to be related to poor cognitive and motor performances.<sup>14,30</sup> In the review by Jandric et al.,<sup>30</sup> there was no clear relation between increased connectivity and earliest stages of the disease, as a compensatory phenomenon, and reduced connectivity in the late phases of the disease, as a result of structural damage progression,<sup>30</sup> as previously thought.<sup>29</sup> Therefore, the causes of decreases or increases in functional connectivity in MS are as yet unclear, mostly because of substantial heterogeneity in studies' methodology and the wide spectrum of clinical characteristics.<sup>30</sup>

Therefore, the results of previously RS-fMRI studies in MS are somewhat discordant. Liu et al.<sup>31</sup> reported decreased connectivity in several brain regions in patients with clinical

isolated syndrome, demonstrating that the dynamics of cortical reorganization is more complex than simple compensation in the early phases of the disease. Alterations in resting-state functional connectivity have been observed throughout the brain in MS patients. Some studies showed a significant increase in global connectivity,<sup>32-35</sup> and others reported decreased connectivity.<sup>33,35</sup> In addition, Tona et al.<sup>36</sup> and Bonavita et al.<sup>37</sup> showed both increased and decreased connectivity in the thalamocortical network and default mode network, respectively. These results demonstrate that the redistribution of cortical connectivity is more complex than a simple trend of increased or decreased connectivity as a compensatory phenomenon or due to damage progression.

In this study, we demonstrated that despite having the disease for a similar length of time, patients using natalizumab had reduced connectivity compared to MS patients who never used this therapy. This difference is potentially due to the late initiation of the natalizumab or maladaptive plasticity. To the best of our knowledge, this is the first study to evaluate resting-state connectivity in MS patients using natalizumab in comparison to controls and MS patients who were never treated with natalizumab.

Several resting-state networks have been shown to be affected in MS patients. The most commonly affected networks are the visual, sensorimotor, and default mode networks.<sup>13</sup> Tommasin et al.<sup>38</sup> found higher connectivity in the default mode, executive control, and bilateral frontoparietal networks, of MS patients, compared to controls. Also, these authors found reduced connectivity between the anterior cerebellar network and executive control network and between the anterior cerebellar network and salience network, in MS patients, compared to controls. In the current study, we found that MS patients not using natalizumab had alterations in the secondary visual network, regardless of whether the participants had active optic neuritis or not, as in previous studies.<sup>35,39,40</sup> Additionally, we found changes in the sensorimotor network in MS patients not using natalizumab, as observed in several previous studies.<sup>32,35,40</sup> Although, we did not find alterations in the default mode network, other researchers also did not observe these differences,<sup>39,40</sup> which may be due to differences in disease duration, MS phenotype, level of cognitive impairment, and treatment adequacy between the studies.

The limitations of this study include its relatively small sample size. Although we were able to demonstrate abnormalities in resting-state connectivity, studies with a larger number of participants may expand the results. As the study was retrospective, we were unable to assess the clinical functional status of the participants at the time of the examination. Therefore, we could not consider clinical characteristics, such as the EDSS in this study. However, we ensured that the groups of MS patients were matched for sex, age, and time from diagnosis, as well as for the hyperintense lesion volume seen on FLAIR, and white matter, gray matter, including thalamus, and whole brain volumes. Also, none of the

participants had active lesions or were using corticosteroids at the time of the study.

## Conclusion

Patients with MS using natalizumab showed decreased connectivity in some resting-state networks when compared to controls and patients not using natalizumab. This decreased connectivity might be due to the late use of a highly efficacious drug, a poor response to other less efficacious drugs, a compensation in response to maladaptive plasticity. Future studies should consider the longitudinal evolution of brain functional connectivity in MS patients using natalizumab since their initial diagnosis.

## Author contributions

Diogo Goulart Corrêa: Made a substantial contribution to the design of the work, drafted the article, approved the version to be published, take public responsibility for appropriate portions of the content of the article.

Eelco van Duinkerken: Made a substantial contribution to the design of the work, drafted the article, approved the version to be published, take public responsibility for appropriate portions of the content of the article.

João Gabriel Dib Farinhais: Made a substantial contribution to the acquisition of data, drafted the article, approved the version to be published, take public responsibility for appropriate portions of the content of the article.

Valéria Coelho Pereira: Made a substantial contribution to the acquisition of data, drafted the article, approved the version to be published, take public responsibility for appropriate portions of the content of the article.

Emerson Leandro Gasparetto: Made a substantial contribution to interpretation of data, revised the article critically for important intellectual content, approved the version to be published, take public responsibility for appropriate portions of the content of the article.

Soniza Vieira Alves-Leon: Made a substantial contribution to analysis of data, revised the article critically for important intellectual content, approved the version to be published, take public responsibility for appropriate portions of the content of the article.

Fernanda Cristina Rueda Lopes: Made a substantial contribution to analysis of data, revised the article critically for important intellectual content, approved the version to be published, take public responsibility for appropriate portions of the content of the article.

## ORCID iDs

Diogo G. Correa  <https://orcid.org/0000-0003-4902-0021>  
Joao Gabriel D. Farinhais  <https://orcid.org/0000-0001-8246-7891>

## REFERENCES

- Thompson AJ, Baranzini SE, Geurts J, et al. Multiple sclerosis. *Lancet*. 2018;391: 1622-1636.

2. Radü E-W, Mueller-Lenke N, Thoeni A, et al. MRI in multiple sclerosis: description of lesions and guidelines for standardized MRI Examinations. *NeuroRadiol J.* 2009;22(1 suppl):43-50.
3. Dobson R, Giovannoni G. Multiple sclerosis - a review. *Eur J Neurol.* 2019;26: 27-40.
4. Wattjes MP, Steenwijk MD, Stangel M. MRI in the diagnosis and monitoring of multiple sclerosis: an update. *Clin Neuroradiol.* 2015;25(Suppl 2):157-165.
5. Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. *Mult Scler.* 2018;24: 96-120.
6. Giovannoni G. Disease-modifying treatments for early and advanced multiple sclerosis: a new treatment paradigm. *Curr Opin Neurol.* 2018; 31: 233-243.
7. Schreiner TL, Miravalle A. Current and emerging therapies for the treatment of multiple sclerosis: focus on cladribine. *J Cent Nerv Syst Dis.* 2012;4:1-14.
8. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. *Lancet Neurol.* 2018;17:162-173.
9. Oreja-Guevara C Overview of magnetic resonance imaging for management of relapsing-remitting multiple sclerosis in everyday practice. *Eur J Neurol.* 2015;22:22-27.
10. Schneider R, Matusche B, Genç E, et al. Microstructural white matter alterations in cognitively impaired patients at early stages of multiple sclerosis. *Clin Neuroradiol.* 2021;31:993-1003.
11. Khanna N, Altmeyer W, Zhuo J, et al. Functional neuroimaging: fundamental principles and clinical applications. *NeuroRadiol J* 2015;28:87-96.
12. Filippi M, Agosta F, Spinelli EG, et al. Imaging resting state brain function in multiple sclerosis. *J Neurol.* 2013;260:1709-1713.
13. Tahedl M, Levine SM, Greenlee MW, et al. Functional connectivity in multiple sclerosis: recent findings and future directions. *Front Neurol.* 2018;9:828.
14. Rocca MA, Schoonheim MM, Valsasina P, et al. Task- and resting-state fMRI studies in multiple sclerosis: from regions to systems and time-varying analysis. Current status and future perspective. *Neuroimage Clin.* 2022;35:103076.
15. Singh MK, Singh KK. A review of publicly available automatic brain segmentation methodologies, machine learning models, recent advancements, and their comparison. *Ann Neurosci.* 2021;28:82-93.
16. Manjón JV, Coupé P. volBrain: an online MRI brain volumetry system. *Front Neuroinform.* 2016;27;10-30.
17. Power JD, Barnes KA, Snyder AZ, et al. Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion. *Neuroimage.* 2012; 59:2142-2154.
18. Power JD, Schlaggar BL, Petersen SE. Recent progress and outstanding issues in motion correction in resting state fMRI. *Neuroimage.* 2015;105:536-551.
19. Beckmann CF, DeLuca M, Devlin JT, et al. Investigations into resting-state connectivity using independent component analysis. *Philos Trans R Soc Lond B Biol Sci.* 2017;360:1001-1013.
20. Nickerson LD, Smith SM, Öngür D, et al. Using dual regression to investigate network shape and amplitude in functional connectivity analyses. *Front Neurosci.* 2017;11:115.
21. Lee MH, Smyser CD, Shimony J. Resting-state fMRI: a review of methods and clinical applications. *AJNR Am J Neuroradiol.* 2013;34:1866-1872.
22. Winkler AM, Ridgway GR, Webster MA, et al. Permutation inference for the general linear model. *Neuroimage.* 2014;92:381-397.
23. Tomassini V, Matthews PM, Thompson AJ, et al. Neuroplasticity and functional recovery in multiple sclerosis. *Nat Rev Neurol.* 2012;8:635-646.
24. Rio J, Tintoré M, Sastre-Garriga J, et al. Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response. *Eur J Neurol.* 2012;19: 899-904.
25. Spelman T, Kalincik T, Zhang A, et al. Comparative efficacy of switching to natalizumab in active multiple sclerosis. *Ann Clin Transl Neurol.* 2015;2:373-387.
26. Prosperini L, Gianni C, Leonardi L, et al. Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis. *Mult Scler.* 2012;18: 64-71.
27. Jalkh G, Abi Nahed R, Macaron G, et al. Safety of newer disease modifying therapies in multiple sclerosis. *Vaccines (Basel).* 2020;9:12.
28. Hoepner R, Faissner S, Salmen A, Gold R, Chan A. Efficacy and side effects of natalizumab therapy in patients with multiple sclerosis. *J Cent Nerv Syst Dis.* 2014;6: 41-49.
29. Sbardella E, Petsas N, Tona F, et al. Resting-State fMRI in MS: general concepts and brief overview of its application. *BioMed Res Int.* 2022;2015:212693.
30. Jandris D, Doshi A, Scott R, et al. A systematic review of resting-state functional MRI connectivity changes and cognitive impairment in multiple sclerosis. *Brain Connect.* 2022;12:112-133.
31. Liu Y, Duan Y, Liang P, et al. Baseline brain activity changes in patients with clinically isolated syndrome revealed by resting-state functional MRI. *Acta Radiol.* 2012;53:1073-1078.
32. Fairv A, Rico A, Zaaraoui W, et al. Assessing brain connectivity at rest is clinically relevant in early multiple sclerosis. *Mult Scler.* 2012;18:1251-1258.
33. Dogonowski AM, Siebner HR, Soelberg Sørensen P, et al. Resting-state connectivity of pre-motor cortex reflects disability in multiple sclerosis. *Acta Neurol Scand.* 2013;128:328-335.
34. Liu Y, Liang P, Duan Y, et al. Brain plasticity in relapsing-remitting multiple sclerosis: evidence from resting-state fMRI. *J Neurol Sci.* 2011;304:127-131.
35. Rocca MA, Valsasina P, Martinelli V, et al. Large-scale neuronal network dysfunction in relapsing-remitting multiple sclerosis. *Neurology.* 2012;79:1449-1457.
36. Tona F, Petsas N, Sbardella E, et al. Multiple sclerosis: altered thalamic resting-state functional connectivity and its effect on cognitive function. *Radiology.* 2014;271: 814-821.
37. Bonavita S, Gallo A, Sacco R, et al. Distributed changes in default-mode resting-state connectivity in multiple sclerosis. *Mult Scler.* 2011;17:411-422.
38. Tommasin S, De Giglio L, Ruggieri S, et al. Multi-scale resting state functional reorganization in response to multiple sclerosis damage. *Neuroradiology.* 2020;62: 693-704.
39. Sbardella E, Tona F, Petsas N, et al. Functional connectivity changes and their relationship with clinical disability and white matter integrity in patients with relapsing-remitting multiple sclerosis. *Mult Scler.* 2015;21:1681-1692.
40. Janssen AL, Boster A, Patterson BA, et al. Resting-state functional connectivity in multiple sclerosis: an examination of group differences and individual differences. *Neuropsychologia.* 2013;51:2918-2929.